Alexander D. Guminski

40 Rocklands Rd
Wollstonecraft, NSW 2065, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 88 publications

Vaccine-induced immunity is maintained in glioma patients relative to other solid tumours.

Vaccine-induced immunity is maintained in glioma patients relative to other solid tumours.

Journal: Journal of neuro-oncology

Published: September 02, 2025

The gut microbiome as a potential predictive biomarker for breast cancer: emerging association and geographic differences.

The gut microbiome as a potential predictive biomarker for breast cancer: emerging association and geographic differences.

Journal: Frontiers in oncology

Published: July 15, 2025

Oral Microbiome as a Biomarker and Therapeutic Target in Head and Neck Cancer: Current Insights and Future Directions.

Oral Microbiome as a Biomarker and Therapeutic Target in Head and Neck Cancer: Current Insights and Future Directions.

Journal: Cancers

Published: July 03, 2025

Extended follow-up outcomes of patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab on EMPOWER-CSCC-1: A retrospective cohort study.

Extended follow-up outcomes of patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab on EMPOWER-CSCC-1: A retrospective cohort study.

Journal: Journal of the American Academy of Dermatology

Published: June 19, 2025

A first-in-human, Phase 1/2a, open-label study of SQ3370, a first-in-class doxorubicin-based click chemistry therapeutic, in patients with advanced solid tumors.

A first-in-human, Phase 1/2a, open-label study of SQ3370, a first-in-class doxorubicin-based click chemistry therapeutic, in patients with advanced solid tumors.

Journal: medRxiv : the preprint server for health sciences

Published: June 12, 2025

Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma.

Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma.

Journal: The New England journal of medicine

Published: June 02, 2025

Surveillance After Treatment of Adenoid Cystic Carcinoma of the Head and Neck: Review of Institutional Outcomes and Proposed Surveillance Imaging Protocol.

Surveillance After Treatment of Adenoid Cystic Carcinoma of the Head and Neck: Review of Institutional Outcomes and Proposed Surveillance Imaging Protocol.

Journal: Journal of medical imaging and radiation oncology

Published: February 08, 2025

Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study.

Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study.

Journal: The Lancet. Oncology

Published: September 26, 2024

Development of a First-in-Class Click Chemistry-Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial.

Development of a First-in-Class Click Chemistry-Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 06, 2024

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study.

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study.

Journal: The Lancet. Oncology

Published: July 09, 2024

Anaplastic thyroid cancer: A review of recent evidence and summary of an Australian institutional protocol.

Anaplastic thyroid cancer: A review of recent evidence and summary of an Australian institutional protocol.

Journal: Asia-Pacific journal of clinical oncology

Published: March 06, 2024

High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.

High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.

Journal: Journal for immunotherapy of cancer

Published: February 14, 2024

Showing 1-12 of 88

Last Updated: 09/26/2026